首页> 美国卫生研究院文献>Blood >Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)
【2h】

Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)

机译:血管内皮通透性过高会诱发克拉克森氏病(全身性毛细血管渗漏综合征)的临床症状

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The systemic capillary leak syndrome (SCLS) is a rare disorder characterized by transient episodes of hypotensive shock and anasarca thought to arise from reversible microvascular barrier dysfunction. Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS suggests a pathogenic contribution of endogenous immunoglobulins, the mechanisms of vascular hyperpermeability remain obscure. Herein, we report clinical and molecular findings on 23 patients, the largest SCLS case series to date. Application of episodic SCLS sera, but neither the purified immunoglobulin fraction nor sera obtained from patients during remission, to human microvascular endothelial cells caused vascular endothelial cadherin internalization, disruption of interendothelial junctions, actin stress fiber formation, and increased permeability in complementary functional assays without inducing endothelial apoptosis. Intravenous immunoglobulin, one promising therapy for SCLS, mitigated the permeability effects of episodic sera. Consistent with the presence of endogenous, nonimmunoglobulin, circulating permeability factor(s) constrained to SCLS episodes, we found that vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang2), were elevated in episodic SCLS sera but not in remission sera. Ab-based inhibition of Ang2 counteracted permeability induced by episodic SCLS sera. Comparable experiments with anti-VEGF Ab (bevacizumab) yielded less interpretable results, probably because of endothelial toxicity of VEGF withdrawal. Our results support a model of SCLS pathogenesis in which nonimmunoglobulin humoral factors such as VEGF and Ang2 contribute to transient endothelial contraction, suggesting a molecular mechanism for this highly lethal disorder.
机译:全身性毛细血管渗漏综合征(SCLS)是一种罕见的疾病,其特征在于低血压性休克和阿那沙卡的短暂发作被认为是由可逆性微血管屏障功能障碍引起的。尽管SCLS中未知意义的单克隆丙种球蛋白病的高发病率表明内源性免疫球蛋白的致病作用,但血管通透性过高的机制仍然不清楚。在此,我们报告了23例患者的临床和分子发现,这是迄今为止最大的SCLS病例系列。在人的微血管内皮细胞中应用间歇性SCLS血清,但未应用纯化的免疫球蛋白级分或从患者获得的血清中,均导致血管内皮钙黏着蛋白内在化,内皮间连接破坏,肌动蛋白应力纤维形成,并在不诱导补充功能的测定中增加通透性内皮细胞凋亡。静脉免疫球蛋白是SCLS的一种有希望的治疗方法,可减轻发作性血清的通透性影响。与内源性,非免疫球蛋白,循环通透性因子(仅限于SCLS发作)的存在相一致,我们发现在发作性SCLS血清中血管内皮生长因子(VEGF)和血管生成素2(Ang2)升高,但缓解期血清中则没有。基于Ab的Ang2抑制作用抵消了情景性SCLS血清诱导的通透性。与抗VEGF Ab(贝伐单抗)相比的实验产生的解释性较差,这可能是因为VEGF撤出对内皮有毒性。我们的研究结果支持了一种SCLS发病机制模型,其中非免疫球蛋白体液因子(例如VEGF和Ang2)促成瞬时内皮收缩,提示这种高度致死性疾病的分子机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号